Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nebulin-related-anchoring protein (NRAP) is a muscle-specific cytoskeletal protein of approximately 1,730 amino acids (~197 kDa), encoded by the NRAP gene on chromosome 10q25.3. It contains a cysteine-rich LIM domain, 11 simple repeats, and 5 super repeats, facilitating interactions with α-actin, talin, actin, vinculin, KLHL41, and muscle LIM protein. NRAP is essential for myofibrillar assembly and force transmission, anchoring terminal actin filaments to the cell membrane at cardiac intercalated discs and skeletal muscle myotendinous junctions. Mutations in NRAP have been identified as causative in rare autosomal recessive forms of cardiomyopathy, notably dilated cardiomyopathy and left ventricular non-compaction cardiomyopathy, due to loss-of-function effects that impair myofibrillar structure and function. While NRAP is critical for muscle architecture, it is not currently considered a direct therapeutic target, and no specific drugs interact with this protein.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nebulin-related-anchoring protein (NRAP).